A Combination of DR5 Agonistic Monoclonal Antibody with Gemcitabine Targets Pancreatic Cancer Stem Cells and Results in Long-term Disease Control in Human Pancreatic Cancer Model
N.V. Rajeshkumar(Johns Hopkins University), Manuel Hidalgo(Hospital Universitario de Fuenlabrada)
Cited by 88
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
|Science|2008|4k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
A DNA methylation fingerprint of 1628 human samples
|Genome Research|2011|418
An <i>In vivo</i> Platform for Translational Drug Development in Pancreatic Cancer
|Clinical Cancer Research|2006|412